SCHEDULE 13G: Affinity Healthcare Fund and Affinity Asset Advisors Disclose 7.83% Stake in Karyopharm Therapeutics

Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC have disclosed a combined beneficial ownership of 7.83% of Karyopharm Therapeutics Inc.'s common stock, primarily through equity call options and a convertible bond.

Summary

• Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC reported beneficial ownership of 664,224 shares of Karyopharm Therapeutics Inc. common stock.
• This represents 7.83% of the Issuer's outstanding common stock.
• The ownership includes 600,100 shares acquirable upon exercise of certain equity call options held by the Fund and 64,124 shares acquirable upon conversion of the Issuer's Convertible Bond due October 15, 2025.
• The percentage is calculated based on 8,480,170 shares of Common Stock outstanding as of February 24, 2025, after giving effect to a reverse stock split effected on that date.
• Both Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC share voting and dispositive power over these 664,224 shares.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by a healthcare-focused fund, which can be viewed as a positive signal of institutional confidence in Karyopharm Therapeutics Inc. However, it does not contain operational or financial performance updates from the company itself, thus limiting a strong positive or negative sentiment.

Positives

• The disclosure of a significant 7.83% stake by a healthcare-focused fund (Affinity Healthcare Fund, LP) and its investment manager (Affinity Asset Advisors, LLC) may signal increased institutional confidence or interest in Karyopharm Therapeutics Inc.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Karyopharm Therapeutics Inc. regarding its future outlook.

Industry Context

This filing indicates a significant investment by a specialized healthcare fund in a therapeutics company, which could reflect a positive outlook on the specific company's prospects or the broader biotechnology and pharmaceutical sector. Such institutional investments are common in the industry as funds seek to gain exposure to promising companies.

Comparison to Industry Standards

• A 7.83% beneficial ownership stake is a substantial institutional position, indicating a significant commitment from Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC to Karyopharm Therapeutics Inc. While direct comparisons to specific companies' ownership structures are not provided in this document, a stake of this size typically places the investor among the larger institutional holders, potentially signaling confidence in the company's long-term value proposition within the biotech industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be perceived positively by existing and potential shareholders, potentially signaling confidence in the company's value.

Key Dates

Keywords

Karyopharm Therapeutics, Affinity Healthcare Fund, Affinity Asset Advisors, Schedule 13G, beneficial ownership, common stock, equity call options, convertible bond, institutional investment